COUMADIN, LANOXIN, DILANTIN NO-SUBSTITUTION POSITION FAVORED IN PHARMACY SURVEY
COUMADIN, LANOXIN, DILANTIN NO-SUBSTITUTION POSITION FAVORED IN PHARMACY SURVEY regardless of whether the generic is required by a third-party plan or cost containment pressures, University of Mississippi Research Institute of Pharmaceutical Sciences' Benjamin Banahan, PhD, said Nov. 8 at the Annual Meeting of the American Association of Pharmaceutical Scientists. Banahan reported the results of a national mail survey, including 830 retail pharmacists and 460 hospital pharmacists, to determine the willingness of pharmacists to dispense generics in place of drugs with narrow therapeutic indices.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth